Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Jun 26, 2026 | Press Releases

Live Presentation and Q&A: Tuesday, June 30, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – June 26, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics...

Phio Pharmaceuticals Announces “How siRNA Therapy can Change the Course of Cancer Treatment” in a Fireside Chat with Force Family Office on Monday, June 29, 2026

Jun 25, 2026 | Press Releases

Live virtual fireside chat – investors, advisors, and life sciences analysts invited to attendKing of Prussia, Pennsylvania–(Newsfile Corp. – June 25, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762

Jun 24, 2026 | Press Releases

Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substanceNewly manufactured supply will support upcoming clinical trial in next development phaseKing of Prussia, Pennsylvania–(Newsfile Corp. – June 24, 2026) – Phio...

Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026

Jun 18, 2026 | Press Releases

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in Phio Pharmaceuticals, to attend the live, interactive presentation and one-on-one meetingsKing of Prussia, Pennsylvania–(Newsfile Corp. – June...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

May 26, 2026 | Press Releases

Live Presentation and Q&A: Thursday, May 28, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – May 26, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using...